Detalles de la búsqueda
1.
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Br J Haematol
; 185(5): 948-951, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30460696
2.
A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.
PLoS One
; 6(5): e19861, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21625473
Resultados
1 -
2
de 2
1
Próxima >
>>